Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Chlordiazepoxide
Drug ID BADD_D00432
Description An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.
Indications and Usage For the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety.
Marketing Status approved; illicit; investigational
ATC Code N05BA02
DrugBank ID DB00475
KEGG ID D00267
MeSH ID D002707
PubChem ID 2712
TTD Drug ID D06BEP
NDC Product Code 71554-014; 61919-593; 12828-0006; 48087-4402; 64330-082
UNII 6RZ6XEZ3CR
Synonyms Chlordiazepoxide | 7-Chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-amine 4-oxide | 7 Chloro N methyl 5 phenyl 3H 1,4 benzodiazepin 2 amine 4 oxide | Methaminodiazepoxide | 7-Chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepine-4-oxide | 7 Chloro 2 methylamino 5 phenyl 3H 1,4 benzodiazepine 4 oxide | Chlordiazepoxide Hydrochloride | Hydrochloride, Chlordiazepoxide | Chlordiazepoxide Monohydrochloride | Monohydrochloride, Chlordiazepoxide | Librium | Chlozepid | Elenium | Chlordiazepoxide Hydrobromide | Hydrobromide, Chlordiazepoxide | Chlordiazepoxide Perchlorate | Perchlorate, Chlordiazepoxide
Chemical Information
Molecular Formula C16H14ClN3O
CAS Registry Number 58-25-3
SMILES CN=C1CN(C(=C2C=C(C=CC2=N1)Cl)C3=CC=CC=C3)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.001---
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009---
Asthenia08.01.01.001---
Ataxia17.02.02.001; 08.01.02.004--
Completed suicide08.04.01.010; 19.12.01.001---
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Dermatitis bullous23.03.01.002--
Diplopia17.17.01.005; 06.02.06.002---
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dry mouth07.06.01.002--
Dysarthria19.19.03.001; 17.02.08.001--
Ecchymosis01.01.03.001; 24.07.06.002; 23.06.01.001---
Eczema23.03.04.006--
Erythema23.03.06.001---
Erythema multiforme23.03.01.003; 10.01.03.015--
Erythema nodosum23.07.02.001; 10.02.01.020---
Extrapyramidal disorder17.01.02.007--
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Feeling abnormal08.01.09.014---
Gait disturbance15.03.05.013; 17.02.05.016; 08.01.02.002--
Hallucination19.10.04.003--
Hepatic function abnormal09.01.02.001---
Hypertonia15.05.04.007; 17.05.02.001---
Hypotension24.06.03.002--
Insomnia19.02.01.002; 17.15.03.002--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004---
Leukopenia01.02.02.001---
Libido decreased21.03.02.005; 19.08.03.001--
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene